Bio-Path Holdings, Inc., (NASDAQ:BPTH) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro.

The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application.

The company expects to begin preclinical studies to confirm these assumptions in the fourth quarter of 2024. These studies are expected to provide crucial insights into the mechanism and efficacy of BP1001-A in enhancing insulin sensitivity and reveal its therapeutic potential for obesity and Type 2 diabetes.

The company also reported completion of enrollment in the third dosing cohort of its ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.

AbbVie Inc (NYSE:ABBV) and Roche Holdings AG's (OTC:RHHBY) Genentech have partnered for Venclexta (venetoclax).

In August, Bio-Path provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.

The cohort enrolled more quickly than projected, within six weeks, which underscores the ongoing need for new treatment options for these relapsed/refractory patients.

Bio-Path says that by targeting the key protein involved in the venetoclax treatment at the mRNA level, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.

Price Action: At last check Tuesday, BPTH stock was up 51.50% at $1.30 during the premarket session.

• Next-Gen Nvidia GPUs Could Be Revealed at CES 2025 – What You Need to Know.